The Finance Ministry’s report emphasizes that government reforms, including GST rationalization, are protecting India’s economy from trade challenges while advocating vigilance against external risks. Despite potential disruptions from the US H-1B visa fee, robust growth and upgraded credit ratings underscore a positive outlook, driven by macroeconomic discipline.
Shailesh Chandra will assume the role of additional director, managing director & CEO of Tata Motors from October 1, 2025, for a three-year tenure, while continuing to lead Tata Passenger Electric Mobility. This appointment follows P B Balaji’s departure to become CEO of JLR Automotive on the same date.
Agriculture Minister Shivraj Singh Chouhan and Russian Deputy PM Dmitry Patrushev convened to bolster bilateral agricultural cooperation and trade. Both nations expressed willingness to establish a formal MoU, focusing on boosting India’s exports and improving market access. They also agreed on academic collaboration and joint ventures in seed traceability systems.
HSBC upgraded Indian equities to ‘Overweight’ due to attractive valuations and strong policies, expecting FII return. A weakening dollar and potential US Fed rate cuts will benefit India, with earnings projected to improve. HSBC identified 11 preferred stocks, forecasting a positive outlook for Indian equities.
India and the US are committed to progressing towards a trade agreement, as stated by the Ministry of Commerce & Industry. During Commerce Minister Piyush Goyal’s visit to the US, both sides discussed potential aspects of the deal and agreed to continue discussions for a mutually beneficial outcome.
Donald Trump’s tariff move impacts Indian pharma stocks. Companies like Sun Pharma, Cipla, and Dr. Reddy’s face potential declines. US represents a major market for Indian exports.
Indian Railways has updated its tender contract conditions to prioritize localization, price variation, and maintenance, aiming for greater procurement flexibility and reduced litigation. The revised framework extends the defect replacement timeframe for contractors and grants zones more procurement autonomy. These changes, coupled with GST compliance measures, support India’s infrastructure expansion plans, including significant additions to…
Asian drug stocks faced a downturn. This followed US President Trump’s tariff threat on imported pharmaceuticals. South Korean and Japanese drugmakers experienced declines. Samsung Biologics and Sumitomo Pharma saw significant drops. Celltrion bucked the trend with a slight gain. Experts suggest limited broader economic impact. The US government’s tariff rate is expected to rise.
